UK markets open in 3 hours 20 minutes

Clinigen Group plc (CLIGF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
8.650.00 (0.00%)
At close: 11:18AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.65
Open8.65
Bid0.00 x 0
Ask0.00 x 0
Day's range8.65 - 8.65
52-week range6.00 - 11.37
Volume116
Avg. volume0
Market cap1.175B
Beta (5Y monthly)1.27
PE ratio (TTM)28.27
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Humanigen Signs Contract With Clinigen for Lenzilumab Managed Access Program in Europe

    BURLINGAME, Calif., October 08, 2021--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ announced today it has entered into an arrangement with Clinigen Group plc ("Clinigen") a global pharmaceutical Services and Products company, to implement a Managed Access Program for lenzilumab ("LenzMAP™").

  • Business Wire

    Clinigen Launches Malaysia Office to Strengthen Presence in Southeast Asia

    Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, has launched its Malaysian business with an office in Kuala Lumpur. The new office is part of Clinigen’s strategy to expand its footprint in Southeast Asia, an important market for the Group.

  • Business Wire

    Clinigen Expands Partnership With Accord Healthcare in Clinical Services Into France

    Clinigen Group plc (AIM: CLIN, ‘Clinigen’), the global pharmaceutical and services company, announces that its Clinical Services (CS) business has expanded its exclusive ’on-demand’ supply service with Accord Healthcare (‘Accord’) into France. Through this arrangement, Clinigen’s CS customers will continue to access the Accord portfolio – both UK and EU packs of product – for their clinical trials worldwide.